Equities analysts forecast that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce earnings of ($0.89) per share for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Sarepta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.29) and the highest estimate coming in at ($0.68). Sarepta Therapeutics posted earnings of ($1.18) per share during the same quarter last year, which indicates a positive year over year growth rate of 24.6%. The business is expected to announce its next quarterly earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full year earnings of ($3.37) per share for the current financial year, with EPS estimates ranging from ($3.74) to ($2.95). For the next year, analysts anticipate that the company will post earnings of ($1.74) per share, with EPS estimates ranging from ($2.91) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the prior year, the firm earned ($1.19) earnings per share. The firm’s quarterly revenue was up 350000.0% on a year-over-year basis.

SRPT has been the subject of a number of research analyst reports. Oppenheimer Holdings, Inc. set a $76.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 8th. Robert W. Baird reiterated an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research report on Sunday, April 23rd. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 target price for the company. in a research report on Monday, May 22nd. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Royal Bank Of Canada cut their target price on shares of Sarepta Therapeutics from $91.00 to $60.00 and set an “outperform” rating for the company in a research report on Friday, April 28th. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and an average price target of $61.28.

In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the sale, the director now directly owns 62,471 shares in the company, valued at approximately $2,561,311. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock worth $3,224,208 over the last 90 days. Company insiders own 9.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of SRPT. Principal Financial Group Inc. raised its stake in Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock valued at $280,000 after buying an additional 129 shares in the last quarter. Legal & General Group Plc raised its stake in Sarepta Therapeutics by 3.9% in the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 663 shares in the last quarter. Sigma Planning Corp raised its stake in Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 930 shares in the last quarter. Bank of Montreal Can raised its stake in Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Sarepta Therapeutics by 2.3% in the second quarter. Rhumbline Advisers now owns 61,462 shares of the biotechnology company’s stock valued at $2,072,000 after buying an additional 1,383 shares in the last quarter. Institutional investors own 64.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Expected to Post Earnings of -$0.89 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/sarepta-therapeutics-inc-nasdaqsrpt-expected-to-post-earnings-of-0-89-per-share.html.

Shares of Sarepta Therapeutics (SRPT) opened at 38.52 on Monday. The stock’s market capitalization is $2.12 billion. Sarepta Therapeutics has a 52 week low of $23.51 and a 52 week high of $63.73. The stock’s 50 day moving average is $35.97 and its 200 day moving average is $32.56.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.